Urocortin protects against ischemic injury via a MAPK-dependent pathway.
Urocortin (UCN), is a peptide related to hypothalamic corticotrophin releasing hormone (CRF) and binds with high affinity to the CRF-R2 beta receptor which is expressed in the heart. UCN prevents cell death when administered to primary cardiac myocyte cultures both prior to simulated hypoxia/ischemia and at the point of reoxygenation after simulated hypoxia/ischemia as assayed by trypan blue exclusion. 3'-OH end labeling of DNA (TUNEL), annexin-V and fluorescence activated cell sorting. The protective effect of UCN is dependent on the p42/p44 mitogen-activated protein kinase (MAPK)-pathway. UCN also reduces damage in isolated rat hearts ex vivo, subjected to regional ischemia/reperfusion with the protective effect being observed when UCN is given either prior to ischemia or at the time of reperfusion after ischemia. Hence, UCN is a cardioprotective agent, which acts when given prior to ischemia or after ischemia at reperfusion.